Targeting atrial fibrillation promoting atrial structural remodeling: is this a viable strategy in patients with heart failure?

Naunyn Schmiedebergs Arch Pharmacol. 2018 Mar;391(3):231-233. doi: 10.1007/s00210-018-1463-y. Epub 2018 Jan 11.

Na Li^{1

2

3

4}, Dobromir Dobrev^{5

6}

¹ Cardiovascular Research Institute, Baylor College of Medicine, Houston, TX, USA. nal@bcm.edu.
² Department of Medicine (Section of Cardiovascular Research), Baylor College of Medicine, Houston, TX, USA. nal@bcm.edu.
³ Department of Molecular Physiology & Biophysics, Baylor College of Medicine, Houston, TX, USA. nal@bcm.edu.
⁴ Baylor College of Medicine, One Baylor Plaza BCM285, Houston, TX, 77030, USA. nal@bcm.edu.
⁵ Institute of Pharmacology, West German Heart and Vascular Center, University Duisburg-Essen, Essen, Germany. dobromir.dobrev@uk-essen.de.
⁶ Faculty of Medicine, University Duisburg-Essen, Hufelandstrasse 55, 45122, Essen, Germany. dobromir.dobrev@uk-essen.de.

No abstract available

Publication types